How is CTEM shaping up as a market — and is it worth investing in?

Executive summary

Continuous Threat Exposure Management started life in 2022 as a Gartner framework — five stages, scope through mobilize — and has since acquired everything a market category needs: analyst sizing reports, a vendor shortlist, an acquisition wave, and a hype problem. This piece is the market read. Our companion research, CTEM as an emerging discipline, covers the operating model itself; here we ask the colder questions. How big is this market really? Who is buying, and what are they actually buying? Is the consolidation a sign of maturity or of a category being absorbed before it stands on its own? And for the two audiences that matter — the CISO allocating next year's budget and the platform team weighing build against buy — is CTEM worth the money?

Short version: the program is worth investing in, with more confidence than we can offer for any single product in the category. The distinction runs through everything below.

The Gartner framing, and the prediction that built the category

Gartner introduced CTEM in 2022 as a five-stage program — scope, discover, prioritize, validate, mobilize — explicitly broader than vulnerability management: misconfigurations, identity risk, excessive permissions and leaked credentials count as exposures alongside CVEs. Attached to it was the line that has appeared on more vendor slides than any other sentence in this corner of the industry: organizations prioritizing their security investments based on a CTEM program will be three times less likely to suffer a breach by 2026.

It is now August 2026, the prediction's due date, and the honest status is: unvalidated. As Vectra's tracker of the claim notes, no empirical breach-rate study has been published; the supporting evidence is directional — better visibility, higher solution adoption among CTEM adopters — not a measured breach differential. That does not make the prediction wrong. It makes it unfalsified marketing, and it should be quoted as a hypothesis, not a result. Adoption signals are more concrete: Gartner survey figures cited across vendor literature (Team Cymru's CTEM primer among others) put 71% of organizations as candidates to benefit and roughly 60% already pursuing or considering a program. Gartner's Hype Cycle for Security Operations 2025 (published June 2025) tracks the same motion from the supply side — vulnerability management dissolving into CTEM, with Adversarial Exposure Validation broken out as its own emerging category covering the validate stage.

Market sizing: pick a number, any number

Ask the sizing houses how big CTEM is and you get answers that disagree by a factor of three or more, which tells you something more useful than any single figure would.

Analyst	Category as defined	Base figure	Forecast	CAGR
Grand View Research	CTEM	$2.70B (2025)	$7.00B by 2033	12.7%
Future Market Insights	CTEM	$1.48B (2026)	$4.22B by 2036	11.0%
Fortune Business Insights	Exposure management (broad)	$5.08B (2026)	$26.99B by 2034	23.2%
Straits Research	Exposure management (broad)	$3.25B (2025)	$23.26B by 2033	27.9%

The spread is not sloppiness; it is definitional. Nobody agrees where CTEM ends and adjacent markets begin — vulnerability management, external attack surface management, cyber asset attack surface management, breach-and-attack simulation, now Adversarial Exposure Validation. Draw the boundary tight and you get Future Market Insights' modest $1.5B; draw it around everything exposure-flavored and Fortune Business Insights hands you $27B by 2034. Two conclusions survive the noise. The category is real — every house sees sustained double-digit growth off a base already in the billions. And the category's edges are contested, which matters for buyers, because a "CTEM platform" quote from two vendors may describe two products with barely overlapping capabilities.

The consolidation wave

The clearest market signal is not a forecast; it is what acquirers are paying for. Tenable's purchase of Vulcan Cyber — roughly $147 million in cash plus $3 million in RSUs, announced in early 2025 and closed that quarter — was explicitly framed as an exposure-management play, folding Vulcan's remediation orchestration and hundred-plus integrations into Tenable One. Omdia's read at the time was that it "may begin a year of consolidation" in exposure management. It did not stay lonely: Tenable had already absorbed Bit Discovery for external attack surface visibility, Rapid7 bought Noetic Cyber for asset inventory context, and by January 2026 Check Point had shipped an AI-driven exposure-management offering unifying threat intel, attack-surface visibility and automated remediation. Meanwhile the platform incumbents — CrowdStrike's Falcon Exposure Management, Microsoft Security Exposure Management — are pulling the category into their suites as a feature rather than a market.

Read plainly: the standalone CTEM vendor is a shrinking species. The capabilities are being bought and bundled into platforms whose gravity is elsewhere — endpoint, cloud, or the vulnerability-management install base. That is normal for a young category, but it has a sharp consequence for buyers: the "CTEM platform" you shortlist today has meaningful odds of being an acquisition line-item in someone else's suite before your three-year contract ends. Buy capabilities and data models, not logos.

Hype versus substance

The substance is real. The exposure problem CTEM names — scanner backlogs of tens of thousands of findings, prioritized by CVSS in a vacuum, disconnected from identity risk and misconfiguration and from any notion of what an attacker can actually reach — is the single most common failure pattern we see in the field. July 2026 made the case unprompted: as we detailed in our July vulnerability analysis, the month's most dangerous exposure in many estates was a CVSS 7.2 command injection that only mattered because of what it chained with and what the appliance could reach. A severity sort cannot see that. An exposure program built on reachability can.

The hype is also real. Three flavors recur. Rebadging: vulnerability-management products renamed CTEM with a dashboard, the five stages present in the marketing architecture and absent in the product. The tool fallacy: CTEM is an operating model — Gartner's own framing is a program — and no SKU delivers scoping decisions, remediation ownership, or the organizational mobilize stage. And metric theater: "exposures discovered" is a vanity number; the only metrics that matter are median time-to-remediate for validated, reachable, business-critical exposures, and the trend line of the reachable attack surface itself. If a vendor cannot show how their prioritization decides reachable, they are selling you a better-sorted backlog.

Worth investing? For security leaders allocating budget

Yes — with sequencing. The program-level bet is as close to safe as security investment gets, because its failure mode is cheap: even if the category label evaporates, you will have built an asset inventory you trust, a prioritization pipeline keyed to exploitability and reachability, and a validation loop that tests assumptions. None of that is wasted under any future label. The product-level bet deserves more suspicion. Practical sequencing, from field experience: fund the data substrate first (you cannot manage exposure on an inventory you do not believe); buy prioritization keyed to reachability and active exploitation, not CVSS; add validation — the Adversarial Exposure Validation slice Gartner now tracks separately — once the first two produce a queue worth validating; and negotiate contracts on the assumption of vendor consolidation, favoring exportable data models over proprietary lock-in. For Indian enterprises there is a regulatory tailwind too: DPDP-era accountability and CERT-In reporting timelines both reward knowing your reachable attack surface before the incident, not after.

Worth investing? The build-versus-buy question

For the platform team, the honest answer splits down the middle of the architecture. The hard, differentiated core of CTEM is a continuously updated graph of assets, identities, permissions, network reachability and controls — the thing that answers "what can an attacker reach from here?" Building that from scratch is a multi-year data-engineering program; underestimating it is the most common way internal CTEM efforts die. The scoping, ownership and mobilization layer, by contrast, is organizational and cannot be bought at all. So: buy (or adopt) the graph substrate and the collectors that feed it; build the program around it. This is, transparently, the architecture Netgraph is built on — the graph-native correlation substrate doubles as the exposure model, which is why we consider the two products of one worldview rather than two line items. The reasoning stands independent of whose graph you use: exposure management without a reachability model is vulnerability management with better fonts.

For the discipline-level treatment — how CTEM actually ends the multi-vendor tool tax in practice — read the companion piece, CTEM as an emerging discipline. For the substrate argument, see the graph-native correlation whitepaper; for the reachability logic applied to a live month of vulnerabilities, the July 2026 vulnerability analysis.

About this research

Authored by Autocops Desk. Market figures, predictions and acquisition details referenced here were verified against public sources at the time of writing — Gartner's published CTEM framing and Hype Cycle for Security Operations 2025, sizing reports from Grand View Research, Future Market Insights, Fortune Business Insights and Straits Research, Tenable's press releases on the Vulcan Cyber acquisition, and Omdia's commentary on exposure-management consolidation — attributed in-line. Published 5 August 2026.

Analyst forecasts are third-party estimates with materially different category definitions; we present the spread deliberately rather than endorsing any single figure. Netgraph competes in adjacent territory to the vendors named, and readers should weigh our build-vs-buy view accordingly — the disclosure is the point.